Www.tandfonline.com

1. Supplemental material. Klein et al. Supplementary Table 1. Response rates, survival, and disease progression data from key clinical studies of novel anti-CD20 monoclonal antibodies (mAbs). Study. No. and type of patients. Treatments* Tumor response rates. ................
................